UK clinical guideline for the prevention and treatment of osteoporosis

被引:699
作者
Compston, J. [1 ]
Cooper, A. [2 ]
Cooper, C. [3 ]
Gittoes, N. [4 ,5 ]
Gregson, C. [6 ,7 ]
Harvey, N. [3 ]
Hope, S. [8 ]
Kanis, J. A. [9 ]
McCloskey, E. V. [10 ]
Poole, K. E. S. [1 ]
Reid, D. M. [11 ]
Selby, P. [12 ]
Thompson, F. [13 ]
Thurston, A. [13 ]
Vine, N. [1 ]
机构
[1] Cambridge Biomed Campus, Dept Med, Cambridge, England
[2] Crawley Fracture Liaison Serv, Crawley, Sussex, England
[3] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[4] Univ Birmingham, Univ Hosp Birmingham NHS Fdn Trust, Ctr Endocrinol Diabet & Metabolism, Birmingham, W Midlands, England
[5] Birmingham Hlth Partners, Birmingham, W Midlands, England
[6] Univ Bristol, Musculoskeletal Res Unit, Bath, Avon, England
[7] Royal United Hosp, NHS Fdn Trust, Bath, Avon, England
[8] Nuffield Orthopaed Hosp, Metab Bone, Oxford, England
[9] Univ Sheffield, Ctr Metab Dis, Sch Med, Sheffield, S Yorkshire, England
[10] Univ Sheffield, Metab Bone, Sheffield, S Yorkshire, England
[11] Univ Aberdeen, Emeritus Prof Rheumatol, Aberdeen, Scotland
[12] Univ Manchester, Metab Bone Dis, Manchester, Lancs, England
[13] Natl Osteoporosis Soc, Camerton, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
Osteoporosis; Fracture; NOGG; Guideline; BONE-MINERAL DENSITY; CORTICOSTEROID-INDUCED OSTEOPOROSIS; ORAL VITAMIN-D; FRACTURE RISK; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; ZOLEDRONIC ACID; HIP FRACTURE; CALCIUM SUPPLEMENTATION; INTERVENTION THRESHOLDS;
D O I
10.1007/s11657-017-0324-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over. Methods Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. Results Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment, lifestyle measures and pharmacological interventions, duration and monitoring of bisphosphonate therapy, glucocorticoid-induced osteoporosis, osteoporosis in men, postfracture care and intervention thresholds. Conclusion The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.
引用
收藏
页数:24
相关论文
共 146 条
[1]   Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study [J].
Abrahamsen, Bo ;
Eiken, Pia ;
Prieto-Alhambra, Daniel ;
Eastell, Richard .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
[2]   Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].
Adler, Robert A. ;
El-Hajj Fuleihan, Ghada ;
Bauer, Douglas C. ;
Camacho, Pauline M. ;
Clarke, Bart L. ;
Clines, Gregory A. ;
Compston, Juliet E. ;
Drake, Matthew T. ;
Edwards, Beatrice J. ;
Favus, Murray J. ;
Greenspan, Susan L. ;
McKinney, Ross, Jr. ;
Pignolo, Robert J. ;
Sellmeyer, Deborah E. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35
[3]  
Albaum JM, 2014, J POPUL THER CLIN PH, V21, pE486
[4]   Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis [J].
Amiche, M. A. ;
Albaum, J. M. ;
Tadrous, M. ;
Pechlivanoglou, P. ;
Levesque, L. E. ;
Adachi, J. D. ;
Cadarette, S. M. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (06) :1989-1998
[5]   Multiple clinical vertebral fractures following denosumab discontinuation [J].
Anastasilakis, A. D. ;
Makras, P. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1929-1930
[6]  
[Anonymous], 2012, OSTEOPOROSIS ASSESSI
[7]  
[Anonymous], 2007, The care of patients with fragility fracture
[8]  
[Anonymous], 2015, EFF SEC PREV FRAG FR
[9]  
[Anonymous], 2016, Multimorbidity: Clinical Assessment and Management
[10]   Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports [J].
Aubry-Rozier, B. ;
Gonzalez-Rodriguez, E. ;
Stoll, D. ;
Lamy, O. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1923-1925